July 12th 2024
“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Impressions of Data and Results from the CLEAR Trial
Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.
Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”
Combining Surgical and Therapeutic Treatment Options in Evolving Field of RCC
March 16th 2022Gennady Bratslavsky, MD, discusses the ever-changing field of treatment options for renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.
As Treatment Options Abound, Clinicians Rely on Risk Stratification for Frontline RCC Management
March 15th 2022Primo Nery Lara, Jr., MD, talks treatment of metastatic renal cell carcinoma in the first-line setting at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.
Choueiri Discusses Results of CLEAR Substudy of Lenvatinib Plus Pembrolizumab in RCC
March 4th 2022At 2022 ASCO GU, Toni K. Choueiri, MD, discussed the CLEAR study and how East Asian patients with renal cell carcinoma derived similar benefit with lenvatinib plus pembrolizumab as the overall trial population.
Atezolizumab/Bevacizumab Demonstrates Comparable OS to Sunitinib for Metastatic RCC
February 22nd 2022The final analysis of the phase 3 IMmotion151 trial did not reveal a significant improvement in overall survival with atezolizumab plus bevacizumab over sunitinib for previously untreated patients with metastatic renal cell carcinoma.